Tivantinib added to erlotinib in nonsmallcell lung cancer: The primary end point was not MET...

Annals of Oncology

Volumn 26, Issue 10, 2015, Pages 2007-2009

  Scagliotti, G V ^a   Di Maio, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; K RAS PROTEIN; ONARTUZUMAB; PLACEBO; PLATINUM DERIVATIVE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIVANTINIB; VASCULOTROPIN; 2 PYRROLIDONE DERIVATIVE; ANTINEOPLASTIC AGENT; MET PROTEIN, HUMAN; QUINOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; DRUG PROTEIN BINDING; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNOHISTOCHEMISTRY; INTENTION TO TREAT ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINATION DRUG THERAPY; LUNG NEOPLASMS; METABOLISM; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG THERAPY, COMBINATION; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; QUINOLINES;

EID: 84943745810     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv334     Document Type: Editorial

References (13)

1. Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 2013; 39: 793-801.
2. Feng Y, Thiagarajan PS, Ma PC. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 2012; 7: 459-467.
3. Munshi N, Jeay S, Li Y et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010; 9: 1544-1553.
4. Basilico C, Pennacchietti S, Vigna E et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 2013; 19: 2381-2392.
5. Sequist LV, von Pawel J, Garmey EG et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011; 29: 3307-3315.
6. Yoshioka H, Azuma K, Yamamoto N et al. A randomized, double-blind, placebocontrolled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV non-squamous non-small-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Ann Oncol 2015; 26: 2066-2072.
7. Scagliotti G, von Pawel J, Novello S et al. Phase III multinational, randomized, double-blind, placebo-controlled study of Tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 2015; 33: 2667-2674.
8. Spigel DR, Ervin TJ, Ramlau RA et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013; 31: 4105-4114.
9. Spigel DR, Edelman MJ, O'Byrne K et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 2014; 32(5s suppl): abstr 8000.
10. Santoro A, Rimassa L, Borbath I et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63.
11. Rimassa L, Porta C, Borbath I et al. Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing phase III clinical trial. Hepat Oncol 2014; 1: 181-188.
12. de Bruin EC, McGranahan N, Mitter R et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014; 346: 251-256.
13. Califano R, Morgillo F, De Mello RA, Mountzios G. Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. Ann Transl Med 2015; 3:81.